IMENCEO
LIVE

Serial Number

79440399

Owner

Novartis AG

Attorney

Maury M. Tepper, III

Filing Date

Nov 12, 2025

Add to watchlist:

No watchlists yet
View on USPTO

IMENCEO Trademark

Serial Number: 79440399

IMENCEO is a trademark filed by Novartis AG on November 12, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Novartis AG (12 trademarks)

CH-4002 Basel

Entity Type: 03

Trademark Details

Filing Date

November 12, 2025

Registration Date

Not Registered

Published for Opposition

May 26, 2026

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 26, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 26, 2026 PUBO
NOTIFICATION PROCESSED BY IB
May 21, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 20, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 6, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 6, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 27, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 7, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 7, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 7, 2026 TROA
REFUSAL PROCESSED BY IB
Mar 26, 2026 RFNT
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 25, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 25, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 25, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 25, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 25, 2026 COAR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 12, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 12, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 30, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 25, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 25, 2026 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 23, 2026 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 1, 2026 REPR